Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax

Fig. 4

EIF4Ai is well tolerated and reduces leukemic burden in vivo. a The effect of CR-1-31-B was tested at day 10 post-transplantation of MOLM-14-Luc cells. CR-1-31-B toxicity was assessed at day 7 in healthy C57BL/6 J mice treated with 0.2 mg/kg CR-1-31-B (red) or vehicle (control, black), except for body weight. b Bioluminescent intensities of NSG mice transplanted with MOLM-14-Luc on Day 8 normalized to day 1 intensity. The bars represent the median values, * p < 0.05, unpaired t-test. c Body weight (left panel) and liver weight (right panel) of healthy C57BL/6 J mice treated with CR-1-31-B on days 1 and 8 or 8 days of treatment respectively. d, e Fractions of B220+ B-cells, CD3+ T-cells and CD11b+Ly6G/C+ myeloid cells in d the peripheral blood and e the bone marrow of vehicle and CR-1-31-B treated mice. f-h Absolute number of f B220+ B-cells, g CD3+ T-cells and h cells contained within each Hardy Fraction in CR-1-31-B and vehicle treated mice within the BM. i-j Colony forming units (CFUs) for i pre-B cells and j myeloid progenitors from vehicle and CR-1-31-B treated bone. Data related to Fig. 4 are shown in Supp. Fig. 3. Footnote: In all graphs except for d mean values with SEM are represented, *p < 0.05 and ns indicates a p > 0.05, paired t-test

Back to article page